发明公开
- 专利标题： OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
- 专利标题（中）： 烯烃核转运调节剂及其用途
-
申请号： EP12736172.3申请日： 2012-01-16
-
公开(公告)号： EP2665362A1公开(公告)日： 2013-11-27
- 发明人: SANDANAYAKA, Vincent, P. , SHACHAM, Sharon , SHECHTER, Sharon , MCCAULEY, Dilara
- 申请人： Karyopharm Therapeutics, Inc.
- 申请人地址： 2 Mercer Road Natick, MA 01760 US
- 专利权人： Karyopharm Therapeutics, Inc.
- 当前专利权人： Karyopharm Therapeutics, Inc.
- 当前专利权人地址： 2 Mercer Road Natick, MA 01760 US
- 代理机构： Potter Clarkson LLP
- 优先权： US201161433501P 20110117
- 国际公布： WO2012099807 20120726
- 主分类号： A01N43/64
- IPC分类号： A01N43/64 ; A61K31/41
摘要：
The invention generally relates to the field of nuclear transport modulators,
e.g. , CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions,
e.g. , in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
e.g. , CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions,
e.g. , in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
公开/授权文献
信息查询
IPC分类:
